Compare AstraZeneca plc (AZN) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Nasdaq Inc — how do they compare? AstraZeneca plc trades at $168.72 (market cap $253.13B), while Nasdaq Inc trades at $91.06 (market cap $49.77B). The key difference: AstraZeneca plc is far larger — about 5.1× Nasdaq Inc's market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | NDAQ | |
|---|---|---|
Market Cap | $253.13B | $49.77B |
Sector | Health | Financials |
52-Week High | $209.48 | $100.98 |
52-Week Low | $137.44 | $76.85 |
Enterprise Value | $279.37B | $56.84B |
Dividend Yield | 1.92% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Nasdaq (NDAQ) trades at $89.21, up 1.28% with a bullish technical signal and strong earnings momentum, beating estimates for three consecutive quarters. The company reported robust 2025 revenue of $8.26 billion and net income of $1.79 billion, with a net margin of 23.03%. Recent news highlights include SK Hynix's Nasdaq debut and positive analyst coverage, with 61% of analysts rating it a buy.
Outlook remains positive given earnings consistency and a $105.60 consensus price target, but risks include high valuation multiples and debt levels. Cash flow volatility from investing and financing activities warrants monitoring, though operational strength supports growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
